ANPEP Antibody

Basic Research Questions

• What is ANPEP and what biological roles make it a significant research target?

  ANPEP (Alanyl Aminopeptidase, also known as Aminopeptidase N or CD13) is a multifunctional zinc metalloprotease that plays key roles in numerous biological processes. As a cell surface enzyme (110 kDa), it cleaves N-terminal amino acids from peptide substrates, contributing to protein catabolism and bioactive peptide generation .

  ANPEP is widely expressed in epithelial cells of the kidney, intestine, and respiratory tract, as well as in granulocytes, monocytes, fibroblasts, endothelial cells, and synaptic membranes in the CNS . Its significance as a research target stems from its involvement in:

  • Immune regulation and inflammatory responses

  • Angiogenesis and tumor progression

  • Peptide hormone metabolism

  • Viral receptor activity (notably for human coronavirus 229E)

  • Neuroinflammatory processes

  Researchers investigating these pathways find ANPEP antibodies invaluable for studying both membrane-bound and soluble forms of this protein in various experimental settings .

• How do I select the appropriate ANPEP antibody for specific research applications?

  Selection of an appropriate ANPEP antibody depends on several methodological considerations:

  Application	Selection Criteria	Technical Considerations
  Western Blot	- Target epitope location - Species reactivity - Validated molecular weight detection (109-110 kDa)	- Consider reducing vs. non-reducing conditions - Typical dilution ranges: 1:500-1:5000
  Immunohistochemistry	- Validated for paraffin-embedded or frozen sections - Background levels in target tissue	- Typical dilution ranges: 1:20-1:200 - Antigen retrieval methods may be required
  Flow Cytometry	- Surface epitope recognition - Compatibility with live cells	- Validated on relevant cell lines (e.g., U937 cells)
  Immunofluorescence	- Subcellular localization capability - Signal-to-noise ratio	- Typical dilution ranges: 1:50-1:200

  For advanced multiplex studies, consider antibodies specifically formulated for conjugation (e.g., those in PBS-only buffers without BSA or azide) . When studying specific ANPEP domains, select antibodies raised against particular regions (e.g., N-terminal region antibodies versus those targeting amino acids 668-967) .

• What controls should be implemented when using ANPEP antibodies in experimental protocols?

  Implementing appropriate controls is critical for interpreting ANPEP antibody results reliably:

  Positive Controls:

  • Cell lines with known ANPEP expression (e.g., U937 human histiocytic lymphoma cells)

  • Tissue samples with established expression patterns (kidney, liver, intestinal epithelium)

  • Recombinant ANPEP protein at known concentrations

  Negative Controls:

  • Primary antibody omission to assess secondary antibody background

  • Isotype control antibodies to evaluate non-specific binding

  • ANPEP-negative cell lines or tissues (validate with literature or knockdown approaches)

  Method-Specific Controls:

  • For Western blot: Loading controls (β-actin, GAPDH) and molecular weight markers

  • For immunoprecipitation: Pre-immune serum control

  • For neutralization experiments: Non-neutralizing ANPEP antibodies as comparators

  When validating new antibody lots, compare results with previously validated lots using identical experimental conditions to ensure consistency in detection sensitivity and specificity .

• What are the recommended protocols for optimizing ANPEP antibody performance in Western blot applications?

  Optimizing ANPEP antibody performance in Western blot requires attention to several methodological aspects:

  Sample Preparation:

  • For membrane-bound ANPEP (110 kDa): Use non-ionic detergents (e.g., Triton X-100) in lysis buffers

  • Include protease inhibitors to prevent degradation

  • Consider reducing conditions, as demonstrated in validated protocols for kidney and prostate tissue samples

  Electrophoresis Parameters:

  • Use 8-10% polyacrylamide gels for optimal separation of high molecular weight ANPEP

  • Load sufficient protein (35-50 μg/lane) to detect endogenous expression

  Transfer and Detection:

  • Transfer to PVDF membranes is recommended over nitrocellulose for higher protein retention

  • Block with 5% non-fat milk or BSA in TBST for at least 1 hour

  • Primary antibody dilutions vary by product (typically 1:500-1:5000)

  • Incubate with appropriate HRP-conjugated secondary antibody

  • Use enhanced chemiluminescence detection systems

  Troubleshooting Guide:

  • High background: Increase blocking time or washing steps

  • No signal: Verify antibody reactivity with positive control (human kidney tissue)

  • Multiple bands: Adjust antibody concentration or consider post-translational modifications

  Validated protocols show successful detection at approximately 150 kDa under reducing conditions using Immunoblot Buffer Group 1 .

Advanced Research Questions

• How can ANPEP antibodies be utilized to investigate the soluble form (sANPEP) in neuroinflammation research?

  Investigating sANPEP in neuroinflammation requires specialized methodological approaches using antibodies:

  Differential Detection Strategies:

  • Select antibodies that recognize epitopes in the extracellular domain (amino acids 668-967) that remain intact in both membrane-bound and soluble forms

  • Use sandwich ELISA with capture antibodies targeting different epitopes than detection antibodies to specifically quantify sANPEP in biological fluids

  Neuroinflammation Research Applications:

  • In vitro: Measure sANPEP release from stimulated human astrocytes using proinflammatory factors (TNF-α, IL-1β, IFN-γ)

  • Ex vivo: Quantify sANPEP levels in CSF from patients with neuroinflammatory conditions

  • In vivo: Utilize neutralizing antibodies against sANPEP to attenuate microglial activation in neuroinflammation models

  Functional Analysis Methods:

  • Combine sANPEP antibodies with enzymatic activity assays to correlate protein levels with function

  • Use neutralizing monoclonal antibodies (e.g., clone WM15 for human ANPEP, clone SL13 for mouse ANPEP) to block sANPEP-induced increases in Angiotensin IV in experimental systems

  • Perform co-immunoprecipitation studies to identify interaction partners (particularly microglial proinflammatory receptors)

  Research has demonstrated that astrocytic sANPEP increases Angiotensin IV levels through its enzymatic activity, which exacerbates neuroinflammation by activating microglial angiotensin type 1 receptors—establishing an important crosstalk mechanism between astrocytes and microglia through the brain renin-angiotensin system .

• What approaches can resolve contradictory data obtained with different ANPEP antibody clones?

  Resolving contradictory results obtained with different ANPEP antibody clones requires systematic investigation:

  Epitope Mapping Analysis:

  • Determine binding sites of different antibody clones:

    • N-terminal region antibodies may detect different forms than those targeting amino acids 668-967

    • Peptide competition assays can confirm epitope specificity

  Cross-Validation Methodology:

  • Employ orthogonal detection techniques:

    Technique	Advantage	Implementation
    Mass spectrometry	Epitope-independent detection	Identify peptides after immunoprecipitation
    RNA analysis	Expression confirmation	RT-PCR/qPCR correlation with protein levels
    Genetic manipulation	Specificity control	CRISPR/siRNA knockdown to validate signal loss

  Antibody Characterization:

  • Assess antibody performance in multiple applications (WB, IHC, flow cytometry)

  • Compare monoclonal vs. polyclonal antibodies against the same target

  • Evaluate antibody affinity and avidity through dilution series

  Biological Complexity Considerations:

  • Post-translational modifications may affect epitope accessibility

  • Different glycosylation patterns can cause molecular weight variations

  • Alternative splicing may result in isoform-specific detection

  When contradictory data persist, consider employing antibody pairs in sandwich assays where both antibodies must recognize the target for signal generation, significantly increasing detection specificity .

• How can ANPEP antibodies be employed to study coronavirus-host interactions in infectious disease research?

  ANPEP antibodies offer several methodological approaches for studying coronavirus-host interactions:

  Receptor Binding Studies:

  • Block-of-infection assays: Pre-treat cells with neutralizing ANPEP antibodies before viral exposure to quantify receptor-dependent entry

  • Competition binding assays: Use labeled viral spike proteins and ANPEP antibodies to map interaction domains

  • Co-immunoprecipitation: Pull down ANPEP-virus complexes to identify additional interaction partners

  Structural Interaction Analysis:

  • Epitope mapping: Use antibodies targeting different ANPEP domains to identify critical virus binding regions

  • Conformational studies: Employ conformation-specific antibodies to detect structural changes upon virus binding

  • Proximity ligation assays: Visualize ANPEP-spike protein interactions in situ within cells

  Functional Consequences Investigation:

  • Monitor ANPEP shedding: Quantify soluble ANPEP release following viral infection using sandwich ELISA

  • Signaling pathway activation: Combine ANPEP immunoprecipitation with phospho-protein analysis

  • Receptor internalization: Track ANPEP endocytosis after viral binding using antibody labeling

  Research has established that ANPEP specifically interacts with the S1 domain of human coronavirus 229E spike protein, serving as its cellular receptor . By selectively blocking this interaction with antibodies, researchers can dissect the molecular determinants of viral tropism and develop targeted antiviral strategies that disrupt receptor engagement.

• What methodologies exist for studying the relationship between ANPEP expression and enzymatic activity using antibody-based techniques?

  Several antibody-based methodologies can be employed to correlate ANPEP expression with enzymatic activity:

  Dual Detection Systems:

  • Combine immunodetection with activity-based probes:

    1. Detect total ANPEP expression using standard antibodies

    2. Use fluorogenic or chromogenic substrates to measure enzymatic activity in the same sample

    3. Calculate activity/expression ratio to determine specific activity

  Functional Antibody Applications:

  • Activity modulation assays:

    Approach	Methodology	Outcome Measurement
    Neutralizing antibodies	Block enzymatic active site	Measure inhibition of Ang III conversion to Ang IV
    Non-neutralizing antibodies	Bind to non-catalytic domains	Compare with neutralizing antibodies as controls
    Domain-specific antibodies	Target regulatory regions	Identify allosteric modulatory effects

  Live-Cell Analysis:

  • Flow cytometry combined with functional assays:

    1. Label cells with non-blocking ANPEP antibodies

    2. Sort cells based on expression levels

    3. Measure enzymatic activity in sorted populations

    4. Correlate activity with surface expression density

  Subcellular Activity Mapping:

  • Immunocytochemistry with activity-based probes:

    1. Detect ANPEP localization with fluorescently-labeled antibodies

    2. Apply membrane-permeable activity-based substrates

    3. Analyze colocalization of expression and activity signals

  Research employing these approaches has demonstrated that sANPEP maintains full enzymatic activity despite being released from cell membranes, as it retains the extracellular catalytic domain that cleaves Ang III to generate Ang IV in neuroinflammatory conditions .

• What are the advanced techniques for validating ANPEP antibody specificity in experimental systems?

  Rigorous validation of ANPEP antibody specificity requires multiple complementary approaches:

  Genetic Validation:

  • CRISPR/Cas9 knockout systems:

    1. Generate ANPEP-null cell lines

    2. Compare antibody signal between wild-type and knockout cells

    3. Complete disappearance of signal confirms specificity

  • siRNA/shRNA knockdown:

    1. Transiently reduce ANPEP expression

    2. Quantify corresponding reduction in antibody signal

    3. Correlate protein reduction with mRNA levels

  Epitope-Based Validation:

  • Peptide blocking experiments:

    1. Pre-incubate antibody with immunizing peptide

    2. Apply to samples and compare with unblocked antibody

    3. Signal abrogation confirms epitope specificity

  • Recombinant protein competition:

    1. Use purified ANPEP protein (recombinant fusion proteins containing amino acids 668-967)

    2. Establish competition curves at varying concentrations

    3. Determine antibody affinity and binding characteristics

  Cross-Reactivity Assessment:

  • Multi-species testing:

    1. Test against samples from different species

    2. Verify concordance with predicted homology

    3. Confirm expected reactivity in human, mouse, and rat samples

  • Paralogue specificity:

    1. Test against related aminopeptidases (e.g., LVRN)

    2. Ensure no cross-reactivity with similar family members

  Orthogonal Method Correlation:

  • Mass spectrometry validation:

    1. Immunoprecipitate with ANPEP antibody

    2. Identify captured proteins by mass spectrometry

    3. Confirm predominant detection of ANPEP peptides

  Advanced validation papers should document the antibody specificity using multiple techniques, including affinity parameters and recognition of both native and denatured conformations for appropriate applications .

• How can researchers design multiplexed assays incorporating ANPEP antibodies for comprehensive biomarker analysis?

  Designing effective multiplexed assays with ANPEP antibodies requires careful methodological planning:

  Antibody Selection Criteria for Multiplexing:

  • Choose antibodies raised in different host species for primary detection

  • Select clones with documented lack of cross-reactivity

  • Utilize conjugation-ready formats (PBS-only buffers without BSA or azide)

  • Validate each antibody individually before combining in multiplex format

  Multiplexed Immunoassay Platforms:

  • Cytometric bead arrays:

    1. Conjugate capture antibodies to spectrally distinct beads

    2. Use detection antibodies with different fluorophores

    3. Validated pairs exist for ANPEP (e.g., 66211-1-PBS capture and 66211-2-PBS detection)

  • Multiplex imaging techniques:

    1. Select antibodies with compatible fixation requirements

    2. Use directly labeled primary antibodies or spectrally distinct secondaries

    3. Include appropriate controls for spectral overlap

    4. Employ sequential staining for antibodies with protocol incompatibilities

  Panel Design Considerations:

  • Biological relevance:

    ANPEP Combination	Research Application	Rationale
    ANPEP + inflammatory markers	Neuroinflammation studies	Investigate relationship between ANPEP and cytokine expression
    ANPEP + angiogenesis markers	Cancer research	Examine role in tumor vascularization
    ANPEP + viral receptors	Infection studies	Study co-receptor dynamics in viral entry

  • Technical optimization:

    1. Titrate each antibody in the multiplex to minimize background

    2. Perform blocking steps to prevent non-specific binding

    3. Validate signal specificity with single-stained controls

  Data Analysis Approaches:

  • Employ multiparametric analysis methods (e.g., clustering, dimensionality reduction)

  • Normalize signals across different markers for comparative quantification

  • Correlate ANPEP levels with other biomarkers at single-cell resolution

  Successful implementation enables simultaneous assessment of ANPEP expression alongside other relevant biomarkers, providing deeper insights into its biological context and regulatory relationships.

Professional Insights on ANPEP Research

• How do soluble and membrane-bound ANPEP forms differ in their biological activities across disease contexts?

  The biological activities of soluble ANPEP (sANPEP) and membrane-bound ANPEP differ significantly across disease contexts, with important methodological considerations for research:

  Biochemical Comparisons:

  Property	Membrane-bound ANPEP	Soluble ANPEP (sANPEP)
  Structure	Type II transmembrane protein (CD13)	Lacks transmembrane domain but retains catalytic domain
  Molecular Weight	150-160 kDa (fully glycosylated)	Variable (typically 100-130 kDa)
  Enzymatic Activity	Cleaves N-terminal amino acids from peptides	Fully enzymatically active
  Detection Methods	Cell surface analysis (flow cytometry)	ELISA in biological fluids

  Disease-Specific Functions:

  • Neuroinflammation: sANPEP released from activated astrocytes converts Angiotensin III to Angiotensin IV, promoting microglial activation through AT1R receptors

  • Cancer: Membrane-bound ANPEP promotes angiogenesis and tumor invasion, while elevated sANPEP in plasma serves as a potential biomarker

  • Inflammatory disorders: sANPEP has been proposed as a biomarker for early-onset chronic graft-versus-host disease and rheumatoid arthritis

  • Viral infections: Membrane-bound ANPEP acts as a receptor for human coronavirus 229E, while sANPEP's role in viral pathogenesis remains less defined

  Research Methodologies:

  • For discriminatory analysis, use antibodies targeting the transmembrane domain (exclusive to membrane-bound form)

  • Employ sandwich ELISA with validated antibody pairs to specifically quantify sANPEP in biological fluids

  • Use neutralizing antibodies (e.g., clone WM15 for human samples, clone SL13 for mouse) to distinguish functional effects

  Understanding these differences is crucial for accurately interpreting experimental results and developing targeted therapeutic approaches that selectively modulate specific ANPEP forms.

• What are the current challenges in standardizing ANPEP antibody-based assays for clinical biomarker applications?

  Standardizing ANPEP antibody-based assays for clinical biomarker applications faces several methodological challenges:

  Analytical Standardization Issues:

  • Epitope heterogeneity: Different antibodies recognize distinct epitopes, affecting detection of glycosylated or processed forms

  • Reference standard variability: Lack of universally accepted recombinant ANPEP calibrators

  • Assay platform differences: Varied methodologies across laboratories complicate result comparison

  Pre-analytical Considerations:

  • Sample type variability: sANPEP measurement in plasma versus serum yields different results

  • Stability concerns: Enzymatically active ANPEP may degrade during storage/handling

  • Extraction efficiency: Membrane-bound ANPEP isolation protocols affect recovery rates

  Clinical Validation Challenges:

  • Biological reference ranges: Insufficient data on normal ANPEP levels across populations

  • Disease-specific thresholds: Lack of established cutoffs for various pathological conditions

  • Confounding factors: ANPEP levels affected by medications, comorbidities, and physiological states

  Standardization Approaches:

  1. Develop consensus antibody panels recognized by international standardization bodies

  2. Establish common calibrators with defined units of measurement

  3. Implement quality control programs with inter-laboratory comparisons

  4. Create detailed standard operating procedures for pre-analytical handling

  Research has identified potential clinical applications for ANPEP as a biomarker in conditions ranging from cancer to inflammatory diseases , but moving from research to clinical application requires addressing these standardization challenges to ensure reliable, reproducible results across different healthcare settings.